Myeloma
Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
Published in Blood Weekly, August 16th, 2007
Kosan Biosciences Incorporated (NASDAQ:KOSN) announced that the TIME-2 trial is open and enrolling patients. This marks the opening of Kosan's Tanespimycin in Myeloma Evaluation or "TIME" registration program for its lead Hsp90 inhibitor, tanespimycin (KOS-953). The TIME program includes two clinical trials: TIME-1 and TIME-2. TIME-1 is a pivotal Phase 3 trial to be conducted in a first-relapse patient population. TIME-2, which is designed to be supportive of the TIME-1 trial, is a Phase 2/3 trial in patients with relapsed-refractory disease. TIME-2 also has the potential to support registration in a relapsed-refractory setting. The TIME program will use Kosan's new, proprietary injectable...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-08-16)
More Articles from Blood Weekly
- American Association of Blood Banks
National blood donor pool significantly smaller than previously thought - Anemia
Burrill Reports Biotech Hit By Market Jitters in July - Cancer
City of Hope Celebrates 'La Gota de la Vida Campaign' With Cristian Castro, Graciela Beltran and Alejandro Lerner as Festival Headliners - Erythropoiesis
Amgen Responds to Final CMS National Coverage Determination on Use of Erythropoiesis-Stimulating Agents in Oncology - Leukemia
Sunesis Pharmaceuticals Reports Second Quarter 2007 Financial Results - Leukemia
The Leukemia & Lymphoma Society Announces Appointment of New Chief Medical Officer - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
